Purple Biotech

PPBT

時価総額 $185万

REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company's intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.

Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development

ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it intends to change the ratio of American Depositary Shares (“ADSs”) to its ordinary shares, no par value per share (the “ADS Ratio”), from the current ADS Ratio of one (1) ADS representing two hundred (200) ordinary shares, to a new ADS Ratio of one (1) ADS representing two thousand (2,000) ordinary shares (the “ADS Ratio Change”).

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers      REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom.

Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant milestones REHOVOT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today financial results for the three months ended September 30, 2025, and provided a business update.

Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 platform, which targets the tumor-associated antigen 5T4, the activating receptor CD3 on T cells and the inhibitory receptor NKG2A on NK and CD8⁺ T cells.

REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that on October 16, 2025, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's American Depositary Shares (ADSs) has been below the minimum $1.00 per share requirement under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive trading days.

REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of an aggregate of 5,999,999 of the Company's American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public offering price of $1.00 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants have an exercise price of $1.00 per ADS, are exercisable immediately upon issuance and will expire twenty-four months from the date of issuance.

REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.

Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms